Literature DB >> 6618678

Efficacy of intravenous immunoglobulin preparations against viral and bacterial infections in mouse protection tests.

W Stephan, H Dichtelmüller.   

Abstract

Our investigation indicates that pretreatment of human immunoglobulin for the elimination of the anticomplementary activity is associated with a loss of activity, the extent of which depends on the type of treatment applied. Laboratory preparations of human IgG were tested in a mouse protection assay using influenza A2-Taiwan virus, tetanus toxin and Salmonella typhimurium as the challenge. There was a 7-28% reduction in efficacy in an intravenous 7S preparation in comparison with an untreated 7S IgG. F(ab')2 fragments showed a 24-65% and Fab fragments an 80-100% reduction in efficacy. Two commercial human 7S products showed approximately 90% efficacy in the Salmonella assay; a commercial, pepsin-treated preparation showed 65-74% efficacy when compared with untreated 7S IgG.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6618678     DOI: 10.1007/bf01641203

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  14 in total

1.  Neutralization kinetics of western equine encephalitis virus by antibody fragments.

Authors:  N E Cremer; J L Riggs; E H Lennette
Journal:  Immunochemistry       Date:  1975-07

2.  ENZYMATIC DIGESTION OF RABBIT GAMMA GLOBULIN AND ANTIBODY AND CHROMATOGRAPHY OF DIGESTION PRODUCTS.

Authors:  A NISONOFF
Journal:  Methods Med Res       Date:  1964

3.  Large scale production of human plasma fractions. Eight years experience with the alcohol fractionation procedure of Nitschmann, Kistler and Lergier.

Authors:  P KISTLER; H NITSCHMANN
Journal:  Vox Sang       Date:  1962 Jul-Aug       Impact factor: 2.144

4.  [On new possibilities of intravenous gamma globulin administration].

Authors:  H E SCHULTZE; G SCHWICK
Journal:  Dtsch Med Wochenschr       Date:  1962-08-24       Impact factor: 0.628

5.  [Tissue distribution of native and enzyme-treated human immunoglobulin (author's transl)].

Authors:  R Vollerthun; H H Sedlacek; H Ronneberger
Journal:  Dtsch Med Wochenschr       Date:  1977-05-06       Impact factor: 0.628

6.  [Elimination of complement fixation of gamma-globulin by chemical modification with beta-propiolactone].

Authors:  W Stephan
Journal:  Z Klin Chem Klin Biochem       Date:  1969-05

7.  Characterization of various immunoglobulin preparations for intravenous application. I. Protein composition and antibody content.

Authors:  J Römer; J J Morgenthaler; R Scherz; F Skvaril
Journal:  Vox Sang       Date:  1982-02       Impact factor: 2.144

8.  [Inhibition of opsonization of E. coli by enzyme-treated gammaglobulin (author's transl)].

Authors:  M Eibl; G Friers
Journal:  Wien Klin Wochenschr       Date:  1978-10-27       Impact factor: 1.704

9.  Clinical tolerance and catabolism of plasmin-treated gamma-globulin for intravenous application.

Authors:  S Barandun; V Castel; M F Makula; A Morell; R Plan; F Skvaril
Journal:  Vox Sang       Date:  1975       Impact factor: 2.144

10.  [Prophylaxis and therapy with gamma globulin. General characterization and clinical use of gamma globulin preparations].

Authors:  S Barandun; F Skvaril; A Morell
Journal:  Schweiz Med Wochenschr       Date:  1976-04-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.